Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albumin-bound paclitaxel + S-1 + oxaliplatin + bevacizumab + PD-1 monoclonal antibody
- Development stage
- Preclinical
- Lead developer
- Sanofi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination therapy consisting of five agents: albumin-bound paclitaxel (a taxane chemotherapy), S-1 (an oral fluoropyrimidine), oxaliplatin (a platinum-based chemotherapy), bevacizumab (an anti-angiogenic monoclonal antibody), and a PD-1 monoclonal antibody (an immune checkpoint inhibitor). Various combinations of these agents have been studied in clinical trials, particularly for gastric cancer, but the specific five-drug combination has limited documentation in the literature.
- Other names
- nab-paclitaxel + S-1 + oxaliplatin + bevacizumab + PD-1 monoclonal antibody
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)DNADPYD (Dihydropyrimidine dehydrogenase)
Beyond the preview
Go deeper on albumin-bound paclitaxel + S-1 + oxaliplatin + bevacizumab + PD-1 monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albumin-bound paclitaxel + S-1 + oxaliplatin + bevacizumab + PD-1 monoclonal antibody.